Biopharmaceutical companies launched only two initial public offerings in the US during August, but eight more drug developers entered the queue, setting up September to be another busy IPO month, rivaling July's nine offerings and June's 14.
Twenty-six of the 47 biopharma firms that went public in the first eight months of 2018 were trading in positive territory as of Aug. 31 and the average return was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?